Background Secondary malignant neoplasms of the liver (SMNL) are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of SMNL mortality trends and disparities in the US. Methods This study analyzed SMNL-related (ICD-10: C78.7) CDC WONDER mortality data (1999–2023), and US Cancer Statistics incidence data for adults ≥ 45 years, stratified by demographics, geography, and primary site. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression. Results SMNL-related AAMR rose from 23.8 (1999) to 25.1 (2023). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing SMNL-related deaths. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs progressively increased across each successive 10-year age group. Non-Hispanic (NH) Blacks had the highest AAMR but with a declining trend, while NH Whites saw a significant increase. West’s AAMRs showed the biggest increase. Rural areas consistently had higher AAMRs. Conclusions SMNL mortality is rising among older US adults, with disparities. Improved primary cancer survival extends the window for metastatic progression, highlighting the need for better detection and management.
Disparities in access and outcomes in advanced malignancies encompass, result from, and are interlinked with a host of dimensions, including genetic factors, racial and gender inequities, and socioeconomic status (SES). There are limited data on the existing disparities in patients with peritoneal carcinomatosis (PC) undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Our review aims to discuss these disparities, highlighting the role of race, gender, SES, and distance from healthcare facilities in the utilization of these crucial therapies. Although equal access to treatment for PC remains a hurdle, there are no disparities in the severity and extent of peritoneal cancer, the aggressiveness of cancer, or its response to treatment between White and African American individuals. Males are more likely to undergo CRS and HIPEC for peritoneal metastasis despite a lower prevalence compared to females. Females, however, have increased overall survival and lower 30-day mortality. There is an association between higher SES and private insurance with better access to such therapeutic modalities. Patients with lower SES have an increased number of comorbidities, delays in diagnosis, and significantly lower overall survival. Lower SES patients are at a further disadvantage, as CRS and HIPEC are complex procedures that require specialized expertise and infrastructure, which is typically concentrated in urban areas. These disparities can be addressed by providing equal access, education, and virtual care solutions, which are essential to bridge these gaps and ensure that all patient populations have the opportunity to benefit from advancements in CRS and HIPEC.